May 1, 2018 / 1:10 PM / 24 days ago

BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD

May 1 (Reuters) - Adverum Biotechnologies Inc:

* ADVERUM BIOTECHNOLOGIES ANNOUNCES LONG-TERM PRECLINICAL EFFICACY DATA ON ADVM-022 GENE THERAPY IN WET AMD

* ADVERUM BIOTECHNOLOGIES - 13-MONTH DATA SHOW EFFICACY, DURABILITY OF PROTEIN EXPRESSION FOLLOWING A SINGLE INTRAVITREAL ADMINISTRATION OF ADVM-022

* ADVERUM BIOTECHNOLOGIES INC - ADVM-022 WAS WELL TOLERATED, WITH NO SERIOUS ADVERSE EVENTS IN STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below